Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 6,918 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36. Following the transaction, the chief executive officer directly owned 526,034 shares in the company, valued at $18,684,727.68. This represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ying Du also recently made the following trade(s):

• On Wednesday, July 2nd, Ying Du sold 7,072 shares of Zai Lab stock. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total value of $855,160.97.
• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total value of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total value of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.

Zai Lab Stock Up 2.6%

ZLAB traded up $0.94 during midday trading on Friday, hitting $36.43. 581,960 shares of the company traded hands, compared to its average volume of 911,726. The company's 50-day moving average is $33.80 and its 200 day moving average is $31.38. Zai Lab Limited Unsponsored ADR has a 52 week low of $16.01 and a 52 week high of $44.34. The firm has a market capitalization of $4.05 billion, a PE ratio of -14.63 and a beta of 0.99.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The business had revenue of $106.49 million during the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. On average, sell-side analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. JPMorgan Chase & Co. raised their price target on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, March 13th. Leerink Partners set a $75.00 price objective on Zai Lab and gave the company an "outperform" rating in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $54.28.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in Zai Lab in the 1st quarter worth approximately $1,073,000. MPM Bioimpact LLC raised its position in shares of Zai Lab by 4.2% during the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock valued at $30,128,000 after buying an additional 33,659 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Zai Lab in the first quarter worth $12,649,000. Cubist Systematic Strategies LLC boosted its position in shares of Zai Lab by 29.0% during the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock worth $3,384,000 after acquiring an additional 21,026 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in Zai Lab by 214.3% during the first quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock valued at $498,000 after acquiring an additional 9,390 shares in the last quarter. Institutional investors own 41.65% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.